Direct Neuronal Reprogramming: Prospects for Brain Regeneration and Challenges in Verifying Cell Conversion
Background: Approaches to replacing lost neurons
Direct neuronal reprogramming aims to convert non-neuronal cells into neurons without passing through a pluripotent state. A review published in Annals of Medicine examines strategies ranging from transcription factors to small molecules and technologies for regulating gene expression, and outlines the validation challenges involved in developing therapies. It synthesizes existing research; it is not a report of a single clinical trial demonstrating the efficacy of a new treatment in patients.
The central nervous system has limited capacity to regenerate after injury. The review’s authors focus on strategies for replacing lost neurons. Cell transplantation is one candidate, but hurdles include transplanted cell survival, connections with existing neural circuits, and immune rejection. Directly converting cells within the body could reduce reliance on transplantation. Even when a patient’s own cells are used, however, the immunogenicity of the approach, including its delivery vehicle, requires separate evaluation.
Key findings: Expanding conversion technologies and the gap in functional validation
A traditional approach covered in the review introduces transcription factors into cells in vitro to alter gene expression. One representative combination, BAM, consists of Ascl1, Brn2, and Myt1l. These factors help reconfigure the gene-regulatory machinery that establishes neuronal traits. Other combinations are being studied depending on the starting cell and the target neuron type.
More recently, research has expanded to attempts to convert support cells in the brain, such as astrocytes, in vivo. Strategies include small molecules that modulate signaling pathways and microRNAs (miRNAs) that regulate gene expression. CRISPR activation (CRISPRa) is presented as an approach to increasing the expression of genes already present in the cell. The review also discusses combining transcription factors with epigenetic regulators or neurotrophic factors. These combinations are research strategies intended to improve cell conversion and survival; they do not constitute clinical evidence that combining different drugs in patients speeds recovery.
Whether cells expressing neuronal markers function as members of mature neural circuits is a separate question. The review points to incomplete maturation of induced cells and difficulties in forming synaptic connections and directing axons to appropriate targets. Persistence of traits from the starting cell, or failure to sufficiently alter its metabolic state, may also constrain conversion. Another limitation is that most in vivo studies have been conducted in rodents. Glial cells in humans and rodents differ in gene expression, inflammatory responses, and chromatin features, making it difficult to generalize results directly.
Implications and outlook: From the origin of new neurons to long-term function
A central question is whether the observed neurons were actually converted from support cells. Lineage-tracing studies that track cell origin have produced conflicting results. According to the review, some NeuroD1-related experiments did not confirm that labeled neurons originated from astrocytes, while some PTBP1-related studies raised the possibility that the observed neurons came from pre-existing neurons. These findings alone do not invalidate all cell-conversion research, but labeling signals alone cannot readily establish a cell’s origin.
For translation into therapy, researchers must assess cell origin, target neuronal subtype, functional maturation, and long-term survival alongside conversion efficiency. They must also determine whether delivery vehicles reach the intended cells and whether off-target conversion or immune responses occur. The review identifies improvements in delivery technologies and standardized validation frameworks as priorities for future work. The evidence provided does not demonstrate recovery of memory in people or reversal of disability caused by brain injury.
Sources: Full review available in Europe PMC, article information in PubMed.
BACKGROUND: Treatment of brain injuries and neurodegenerative disorders is a critical challenge due to poor regenerative capabilities of the central nervous system. The current therapeutic strategies are primarily focussed on treating the symptoms than addressing the core issue of loss of neurons. Despite advances in stem cell therapies and surgical alternatives, they are not always successful due to challenges like immune rejection and limited efficacy. Direct neuronal reprogramming of endogenous somatic cells is a promising approach to restore lost neurons. This review evaluates traditional reprogramming techniques and their limitations, explores novel DISCUSSION: Traditional neuronal reprogramming is based on CONCLUSIONS: Direct neuronal reprogramming offers a viable strategy for replenishing neuronal cell mass in neurodegenerative diseases and brain injuries through autologous therapy. Novel This article aims to explain direct neuronal reprogramming as focused treatment for the root causes of neurodegenerative diseases, replenishing lost neuronal cell mass.
The practical value of direct neuronal reprogramming depends on whether it can produce the required neuronal type and connect it functionally to existing circuits. For Parkinson’s disease, one research scenario would be to induce cells with dopaminergic neuron characteristics, then assess their origin, electrophysiological function, circuit integration, and long-term survival. Research institutions and developers need to examine this functional validation and delivery safety alongside conversion efficiency. In particular, they must determine whether results from rodents can be reproduced in human cells and the human brain environment. Using a patient’s own cells could reduce the burden of transplantation, but separate evidence would be needed to conclude that immunosuppressants are unnecessary or that patients’ function is restored.